ESTROGEN RECEPTOR DEGRADING PROTACS

摘要

The specification generally relates to compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, where R¹, R², R³, R⁴, R⁶, R⁷, R⁸, Linker, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.